Why Intercept Pharmaceuticals (ICPT) Stock Is Spiking In Pre-Market Trading Today

NEW YORK (TheStreet) -- Intercept Pharmaceuticals  (ICPT) shares are up 45.88% to $346 in pre-market trading on Tuesday after releasing positive data on its fatty liver drug treatment, obeticholic acid (OCA).

The new data shows OCA reduced the signs and symptoms of non-alcoholic steatohepatitis (NASH) compared to placebo. NASH is a disease of the liver that affects 2% to 5% of Americans and has no current treatment.

Intercept plans to start a phase III study of OCA in NASH next year.

Highlights from the analysis by TheStreet Ratings Team follows:

ICPT Chart ICPT data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE

More from Markets

What Market Selloff? Dow Futures Are Popping on Sunday

What Market Selloff? Dow Futures Are Popping on Sunday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric